跳至主要内容
临床试验/NCT01194700
NCT01194700已完成4 期

Comparative Study of Lung Bioavailability of HFA-Seretide Via Current Spacer Devices in Healthy Volunteers

Brian J Lipworth1 个研究点 分布在 1 个国家目标入组 19 人开始时间: 2009年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
19
试验地点
1
主要终点
Overnight Urinary Cortisol creatinine ratio

研究概览

简要总结

The purpose of this study is to determine the effect of plastic spacers and breath actuated spacers on respirable drug delivery of combination steroid inhaler (Seretide/Advair) and whether electrostatic charge within plastic spacers has a clinically relevant impact on the inhaled steroid delivery.

详细描述

Conventional plastic spacers are bulky and can be influenced by electrostatic charge, which can reduce respirable dose delivery especially when used brand new "out of the box". Breath actuated integrated vortex spacer (Synchro-Breathe) is a compact palm sized antistatic device with a vortex chamber which is designed to be more patient friendly and free from the effects of electrostatic charge. The systemic bioavailability from the lung of inhaled fluticasone and salmeterol is dependent on respirable dose delivery, and hence the performance of inhaler devices can be quantified by measuring the degree of adrenal suppression and fall in serum potassium(K) as surrogates for delivered lung dose. This study attempts to compares the systemic bioavailability from the lung in real life conditions for Fluticasone/Salmeterol combination (measured in terms of relative adrenal suppression and fall in serum K) via the breath actuated Synchro-Breathe device, pMDI( Seretide Evohaler), and Aerochamber Plus & Volumatic spacer used brand new "out of the box" in healthy volunteers.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Healthy Volunteers
  • •Male or female 18-65
  • •Informed Consent
  • •Ability to comply with the requirements of the protocol

排除标准

  • •No respiratory disease
  • •Recent respiratory tract infection (2 months).
  • •Any other clinically significant medical condition such as unstable angina, acute myocardial infarction in the preceding 3 months, recent TIA/ CVA,that may endanger the health or safety of the participant, or jeopardise the protocol.
  • •Any significant abnormal laboratory result as deemed by the investigators
  • •Pregnancy, planned pregnancy or lactation
  • •Known or suspected contra-indication to any of the IMP's
  • •Concomitant use of medicines (prescribed, over the counter or herbal) that may interfere with the trial

研究组 & 干预措施

Evohaler

Experimental

干预措施: Seretide 250(8puffs) via Evohaler actuator (Drug)

Evohaler

Experimental

干预措施: Seretide 250/placebo via Synchro-Breathe (Drug)

Volumatic spacer

Experimental

干预措施: Seretide 250/placebo 8 puffs via Aerochamber Plus spacer (Drug)

Volumatic spacer

Experimental

干预措施: Seretide 250/placebo via Synchro-Breathe (Drug)

Synchro-Breathe

Experimental

干预措施: Seretide 250/placebo via Synchro-Breathe (Drug)

Evohaler

Experimental

干预措施: Seretide 250 (8 puffs)/placebo via Volumatic spacer (Drug)

Aerochamber Plus

Experimental

干预措施: Seretide 250 (8 puffs)/placebo via Volumatic spacer (Drug)

Evohaler

Experimental

干预措施: Seretide 250/placebo 8 puffs via Aerochamber Plus spacer (Drug)

Aerochamber Plus

Experimental

干预措施: Seretide 250/placebo 8 puffs via Aerochamber Plus spacer (Drug)

Aerochamber Plus

Experimental

干预措施: Seretide 250/placebo via Synchro-Breathe (Drug)

Synchro-Breathe

Experimental

干预措施: Seretide 250(8puffs) via Evohaler actuator (Drug)

Synchro-Breathe

Experimental

干预措施: Seretide 250/placebo 8 puffs via Aerochamber Plus spacer (Drug)

Volumatic spacer

Experimental

干预措施: Seretide 250 (8 puffs)/placebo via Volumatic spacer (Drug)

Volumatic spacer

Experimental

干预措施: Seretide 250(8puffs) via Evohaler actuator (Drug)

Aerochamber Plus

Experimental

干预措施: Seretide 250(8puffs) via Evohaler actuator (Drug)

Synchro-Breathe

Experimental

干预措施: Seretide 250 (8 puffs)/placebo via Volumatic spacer (Drug)

结局指标

主要结局

Overnight Urinary Cortisol creatinine ratio

时间窗: within 24 hours after study drug inhalation

This outcome measure evaluates the amount of cortisol being suppressed after inhaled steroid administration. This helps to assess the systemic effect of steroid inhalation and therefore the propensity for adrenal suppression which is a noted adverse effect with high dose inhaled steroids

次要结局

  • Serum Potassium(60 minutes post treatment)

研究者

发起方
Brian J Lipworth
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Brian J Lipworth

Professor (Clinical) Airway allergy and COPD

University of Dundee

研究点 (1)

Loading locations...

相似试验